BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: LPTN.OB) |
 |
 |
| Wednesday, 25 November 2009 21:13 |
 The BioMedReports.com research download section has been updated to include PDFs for two recent research reports written by Griffin Securities for Clinical Data (NASDAQ: CLDA) and Lpath, Inc. (OTC: LPTN.OB). Lpath received a buy rating with a $5 per share 12-month price target while CLDA was rated a buy with a 12-month price target of $38 per share. Below is a summary of both companies from their respective reports. Lpath, Inc. is a biotechnology company focused on lipidomics-based therapeutics that target bioactive signaling lipids for treating a wide range of human disease and is the only company to have developed monoclonal antibodies against bioactive lipids. The Company is currently advancing three early-stage (poised to enter Phase 2 clinical studies) drug candidates (ASONEP™; iSONEP™; and Lpathomab™) in addition to a drug-discovery platform known as ImmuneY2™ which Lpath is leveraging to further expand its pipeline.
In early June, Clinical Data announced positive top-line results from the second of two Phase 3 trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD). In the study, vilazodone achieved statistically significant results on the primary endpoint and secondary efficacy endpoints related to MDD. Study results suggest that vilazodone was generally well-tolerated and the efficacy and safety data were consistent with the findings from the previous Phase 3 trial. Clinical Data intends to file these data as the second of two positive registration studies in support of a New Drug Application (NDA) with the FDA for vilazodone for the treatment of MDD during 1Q10.
CLDA is also evaluating Stedivaze (apadenoson) in an ongoing Phase 3 clinical trial as a cardiac stress imaging agent. Stedivaze is used to identify the symptoms of coronary artery disease (CAD) with patent protection through 2027 and estimated peak sales potential of $523 million. On 11/18/09, CLDA announced the start of the Phase 3 trial of Stedivaze, which is a selective A2A receptor agonist, in development for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) scans (aka cardiac stress tests), which are used to identify symptoms of CAD.
Stedivaze is a highly selective, high affinity agonist of the adenosine A2A receptor. The initiation of the trial followed a meeting with the FDA that reviewed Phase 2 data showing a rapid onset and offset of action following bolus dosing and improved tolerability over marketed products, such as Adenoscan (adenosine) by Astellas Pharma. The trial is expected to enroll approximately 750 patients over an 18–24 month period with an estimated date of 11/30/11 to complete this process.
The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.
Disclosure: No positions. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 3 hours ago
A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY
about 4 hours ago
$JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 5 hours ago
$PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 6 hours ago
Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 7 hours ago
When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 8 hours ago
Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 8 hours ago
Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 11 hours ago
Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9
Free Phone Trade Alerts
